Avantor, INC

Avantor announced its second quarter 2026 financial results, reporting net sales of $1,692.3 million and adjusted EPS of $0.21, while increasing full-year guidance.

Avantor, Inc. subsidiary obtains new senior secured Euro-denominated term loans, refinancing existing debt with a slightly lower interest rate spread.

Avantor, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors, advisory votes on executive compensation, and ratification of its independent auditor.

Avantor announced its first quarter 2026 financial results, reporting flat net sales and a decrease in net income, while reaffirming its full-year guidance.

Avantor, Inc. has appointed Ludovic Brellier as Executive Vice President of Bioscience & Medtech Products and Chief Transformation Officer, effective May 1, 2026.

Avantor announces the resignation of CFO R. Brent Jones, with Steven Eck named interim CFO, while reaffirming its fiscal 2026 financial guidance.

Avantor, Inc. reported Q2 2026 results showing a slight increase in net sales driven by its VWR Distribution & Services segment, while the Bioscience & Medtech Products segment experienced a decline.

Avantor, Inc. reported flat net sales for the first quarter of 2026 compared to the prior year, with a 4.1% organic net sales decrease, while facing margin contractions due to inflationary pressures and higher costs.

Avantor, Inc. reported a significant net loss of $711.8 million for Q3 2025, primarily driven by a $785.0 million goodwill impairment charge, alongside declining sales and margins.

Avantor, Inc. reported a decline in net sales and net income for the second quarter and first half of 2025, primarily due to reduced customer demand and the divestiture of its Clinical Services business, despite progress on its cost transformation initiative.

Avantor reports a decrease in net sales for Q1 2025, impacted by reduced customer demand and a divestiture, while advancing its cost transformation initiative.

Avantor Inc. reported a slight decrease in net sales and a significant drop in net income for the third quarter of 2024, while also announcing the sale of its Clinical Services business.

Avantor, Inc. reported a net loss of $530.2 million for fiscal year 2025, primarily driven by a significant goodwill impairment charge and declining net sales, despite a debt refinancing and cost transformation efforts.

Avantor's 2024 10-K filing reveals a strategic shift towards Laboratory Solutions and Bioscience Production, alongside a cost transformation initiative aimed at $300 million in annual savings by 2026.

Avantor, Inc.'s 2023 10-K filing reveals a 7.3% decrease in net sales and a strategic transition to two new business segments.

Claudius Sokenu, EVP, Chief Legal & Compliance of Avantor, Inc., reported a transaction in 1,201 shares of common stock on July 24, 2026.

Avantor, Inc. reports that Director Mala Murthy was granted restricted stock units (RSUs) vesting in May 2027.

Avantor, Inc. Director Gregory T. Lucier has reported transactions involving restricted stock units and common stock purchases.

Avantor, Inc. reports a grant of restricted stock units to Director Simon Dingemans, vesting in May 2027.

Avantor, Inc. reports that Director Louise Makin was granted restricted stock units vesting in 2027.

Avantor, Inc. reports that Director Joseph Massaro was granted restricted stock units on May 7, 2026, vesting on May 7, 2027.

Avantor, Inc. announces a new CEO, significant board changes, and a comprehensive 'Revival' program aimed at strengthening its business and enhancing shareholder value, despite reporting a net loss in 2025.

Avantor, Inc. announces its 2025 Annual Meeting of Stockholders to be held on May 8, 2025, and provides information on accessing proxy materials and voting.

Avantor's 2025 proxy statement details the agenda for the annual stockholders meeting, including director elections, auditor ratification, and executive compensation approval.

Avantor, Inc. announces its 2024 Annual Meeting of Stockholders to be held on May 9, 2024, outlining key proposals for shareholder voting.

Avantor's proxy statement details the company's director nominees, corporate governance practices, and executive compensation for the upcoming 2024 Annual Meeting of Stockholders.

Vanguard Capital Management reports beneficial ownership of 35,802,263 shares, representing 5.29% of Avantor Inc.'s common stock as of March 31, 2026.

The Vanguard Group has amended its Schedule 13G for Avantor Inc., reporting 0% beneficial ownership following an internal realignment where subsidiaries will now report separately.

T. Rowe Price Investment Management, Inc. has filed an Amendment No. 7 to Schedule 13G, disclosing a 4.8% beneficial ownership stake in Avantor Inc.

BlackRock, Inc. has filed an Amendment No. 5 to Schedule 13G, disclosing a continued beneficial ownership of 8.7% of Avantor, Inc.'s common stock as of September 30, 2025.

T. Rowe Price Investment Management, Inc. has disclosed an 8.3% beneficial ownership stake in Avantor Inc., holding over 56.5 million shares of common stock.

Dodge & Cox, an investment adviser, has disclosed a significant beneficial ownership stake of 17.2% in Avantor, Inc. common stock as of June 30, 2025.